Most material SEC filings — August 4, 2026

Electronic Arts completed its acquisition by a consortium of PIF (Saudi Arabia's Public Investment Fund), Silver Lake Partners, and Affinity Partners on an unspecified date in late 2025. EA shareholders received $210 in cash per share; the deal was announced September 29, 2025, and approved by stockholders December 22, 2025. EA's common stock ceased trading and delisted from NASDAQ. The filing also includes amended charter and bylaws reflecting the private company structure.

Integer Holdings Corporation agreed to be acquired by Armstrong Parent, Inc. (backed by KKR Core II) for $127.00 per share in cash, dated August 2, 2026. The merger is structured with Merger Sub merging into Integer, with Integer becoming a wholly owned subsidiary of Parent. As of July 30, 2026, 34.768 million Integer common shares were outstanding. The transaction is subject to customary closing conditions including regulatory approvals, financing, and stockholder approval.

Future FinTech Group Inc. (market cap ~$13.0M) issued 12,750,000 common shares at $1.00 per share to 16 purchasers (Wealth Index Capital Limited and 15 individuals, all based in China) for total proceeds of $12.75M. Agreement dated July 29, 2026, includes 19.99% ownership cap per Regulation D/S, restrictive legend, and lock-up provisions. Pre-issuance company had 2,080,831 shares outstanding; post-closing dilution approximately 612% (12.75M new shares vs. 2.08M existing).

RYTHM reported Q2 2026 continuing operations revenue of $23.0M (up 73% sequentially from $13.3M in Q1), net income of $1.2M, and adjusted EBITDA of $6.4M. Cash position strengthened to $41.9M via $8.7M operating cash flow. Key driver: amended licensing deal with Green Thumb Industries imposing fixed $70M annual fees (effective April 1, 2026). However, management withheld Q3 guidance citing uncertainty from pending federal prohibition of hemp-derived THC products effective November 12, 2026—creating existential regulatory risk to core business model. Company has 2.2M shares outstanding; 11.0M warrants and 3.0M conversion shares also outstanding.

Richard E. Uihlein, Galectin's Chairman and largest shareholder, converted $105.8 million in outstanding debt (principal $91.0M + accrued interest $14.8M) into 34,376,167 shares of common stock on July 31, 2026, at a blended average conversion price of $3.07/share. This eliminates all debt under five line-of-credit facilities (a sixth $10M undrawn facility remains available). Post-conversion, 100,849,644 shares are outstanding.

RE/MAX Holdings (NYSE: RMAX) and The Real Brokerage (NASDAQ: REAX) announced the August 18, 2026 deadline for RE/MAX shareholders to elect the form of merger consideration in Real's pending acquisition. Shareholders can elect cash or stock (0.515 shares of Real REMAX Group Inc. post-consolidation) per RE/MAX share, with the default being 5.15 shares (adjusted to 0.515). The transaction creates Real REMAX Group Inc. and remains subject to shareholder and regulatory approvals.

Mangoceuticals (MGRX, ~$14.7M market cap) received a 180-calendar-day extension from Nasdaq until February 1, 2027 to regain compliance with the $1.00 minimum bid price requirement (10 consecutive business days). The company may execute a reverse stock split if needed. Concurrently, Mangoceuticals is advancing a definitive business combination agreement with Nuclea Energy Inc., a nuclear microreactor developer, which the CEO calls 'transformative' and a pivot from the company's current men's health telemedicine business (MangoRx).

DigitalBridge signed a definitive merger agreement on December 29, 2025, whereby SoftBank Group Corp. will acquire all outstanding common shares at $16.00 per share in an all-cash transaction. The deal has been approved by stockholders and remains subject to closing conditions. 2Q26 GAAP net income was $212.7M ($1.15/share); Distributable Earnings were $17.8M ($0.09/share). Fee-related earnings declined 17% YoY to $26.6M; FEEUM was $40.2B (+1% YoY). The company refinanced $300M in corporate debt maturing June 2031 at 6.3% blended rate.

PrimeEnergy Resources and lenders (Citibank NA, Fifth Third Bank, West Texas National Bank, SouthState Bank, U.S. Bank NA) executed a Borrowing Base Agreement effective August 3, 2026, reducing the company's borrowing base from $115 million to $105 million. This constitutes a scheduled redetermination under the Fourth Amended and Restated Credit Agreement dated July 5, 2022. The company must deliver mortgages covering ≥90% of borrowing base value and title information on ≥85% of properties within 45 days.

DataMeds AI signed an Amended and Restated Letter of Intent (July 29, 2026) to acquire: (1) QLPM intellectual property from EOS Technology Holdings (19.9% post-closing ownership) and Scilex Holding Company (19.9%); (2) expand Datavault AI Health license from Datavault AI Inc. (19.9%); and (3) acquire controlling interest in Tollo Health/Health Lives Here from HealthBridge Advisors (24.9%). Consideration is Acquisition Stock only; existing public shareholders retain 10.4%. Closing conditioned on $2M+ immediate capital from Dawson James investors, liability reduction, stockholder approval, and Nasdaq compliance. Transaction includes 6-month lockup, board seat appointments, and registration rights for major shareholders.

Consolidated FY2025 revenues declined 12.5% to $3,769.3M (vs. $4,308.2M in 2024), with net loss of $60.1M vs. profit of $142.3M in 2024. Operating profit swung from $244.8M (5.7% margin) to loss of $22.1M (–0.6% margin). Return on equity turned negative at –11.4% (2024: 30.1%). YTD H1 2026 shows continued weakness: revenues $1,608.1M (down 14% YoY), net losses of $62.1M, operating losses of $46.4M. Restructuring charges total $38.4M in 2025 and $3.3M in H1 2026. Gross margins compressed from 20.8% (2024) to 16.8% (2025).

On July 30, 2026, VSeE Health received notice of failure to satisfy continued listing standards (Item 3.01). No specific deficiency, cure period, or exchange is named in the filing text provided. The company's public market value is approximately $18.2M.

Cumberland Pharmaceuticals completed sale of FDA-approved branded business to Apotex Health (largest Canadian pharmaceutical company) for $100M cash plus $11M for inventory/transition, closing July 1, 2026. Board approved special dividend of $1.50/share paid July 31, 2026 to ~15M shares outstanding (~$22.5M total). Company retains development pipeline (four Phase 2 programs including ifetroban) and majority stake in Cumberland Emerging Technologies; transitions to development-stage focus. Transaction approved by >99% shareholder vote.

Z Squared Inc. (Nasdaq: ZSQR, market cap ~$28.2M) signed definitive agreement to acquire 100% of Paradox Data LLC, an AI data center developer in El Dorado, Arkansas. Consideration: $5.0M Series A Preferred Stock at closing (convertible at $7.45/share) plus up to $20.0M additional preferred stock tied to four development milestones (initial AI energization, then 50/100/150 MW capacity thresholds). No cash paid; all-stock deal. Closing targeted within 30 days; outside date September 30, 2026 (extendable to December 31).

Global Business Travel Group reported Q2 2026 revenue of $870M (vs. $631M YoY, +38%); Adjusted EBITDA $178M (vs. $133M, +34%); net income $17M (vs. $15M, +14%). LTM Total New Wins Value accelerated to $3.5B with major wins from Google, Koch, and Pfizer; 95% customer retention maintained. Shareholder approval for Long Lake Management acquisition obtained August 3, 2026; merger expected to close H2 2026 subject to regulatory approvals. Free Cash Flow surged 281% to $103M YoY.

Nuvectis completed an in-licensing deal with Haisco Pharmaceutical Group for ex-China rights to ciprocopan (NXP100), a Complement Factor B inhibitor approved in China in July 2026 for PNH, and NXP200, a BRAF inhibitor. In July 2026, the company raised $115M gross in a follow-on offering anchored by leading healthcare investors, extending cash runway to 1H 2029. Ciprocopan is now the lead candidate; IND meetings and submissions expected 4Q2026 for U.S. regulatory efforts.

IDEAYA's registrational OptimUM-02 trial of darovasertib + crizotinib met its primary endpoint in 313 HLA*A2:01-negative metastatic uveal melanoma patients, showing median PFS of 6.9 months vs. 3.1 months (HR 0.42, p=0.0001). In June 2026, IDEAYA raised $323.4M net from equity offering (7.2M shares + 5.6M pre-funded warrants) and $33.1M from at-the-market offering, bringing cash to $1.24B with runway into 2030 unchanged. NDA filing underway under real-time oncology review with H2 2026 target completion.

Lipocine's Phase 3 trial for LPCN 1154 (oral brexanolone) for postpartum depression failed to meet its primary endpoint of statistically significant HAM-D score reduction vs. placebo at hour 60 in the 90-patient trial (April 2, 2026). Post hoc analysis identified data anomalies at one high-enrolling site; excluding that site, the drug showed positive results. The company plans an FDA guidance meeting (Q3 2026) and will initiate a new Phase 3 trial. Cash increased to $23.3M (June 30, 2026) from $14.9M (Dec 31, 2025); Q2 2026 net loss was $2.6M vs. $2.2M in Q2 2025; royalty revenue rose to $190K from $123K year-over-year.

On July 31, 2026, Resideo Technologies entered into a Separation and Distribution Agreement with ADI Global Distribution Inc. (ADI SpinCo) to separate into two publicly traded companies. ADI SpinCo will receive 75,918,198 shares of common stock, 150,000 shares of preferred stock, and $900 million in cash from Resideo. Resideo will distribute 100% of ADI SpinCo common stock to shareholders on a 1-for-2 ratio. The transaction is structured to be tax-free under IRC Section 355 and Section 368(a)(1)(D).

Hut 8 closed $7.5 billion in non-recourse, investment-grade project financing across River Bend ($3.25B senior secured notes) and Beacon Point Phase 1 ($4.25B senior secured notes, Baa2-rated) in Q2 2026. The company signed a second 352 MW lease at Beacon Point with same investment-grade tenant for ~$9.8B base-term value (~$655M avg annual NOI), bringing total portfolio to 949 MW contracted capacity with ~$26.6B aggregate contract value and >$1.75B expected avg annual NOI. Additionally refinanced $200M Bitcoin-backed facility from 9.0% to 7.0% with FalconX, releasing ~3,300 BTC collateral.

DigitalOcean reported Q2 2026 revenue of $281 million, up 29% YoY, with ARR reaching $1,125 million (+29% YoY). AI Customer ARR surged 212% YoY to $234 million. The company raised 2026 full-year revenue guidance to $1.170–$1.180 billion (30–31% growth) and expects 35%+ growth by Q4 2026. RPO increased dramatically to $894 million from $71 million a year ago, representing major customer commitments; the company signed first nine-figure annual contracts and extended weighted average contract life to 3+ years. Balance sheet strengthened with $767 million cash; the company repurchased ~$472 million of convertible notes via follow-on offering.

Arvinas secured FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader approved by the FDA, for ER+/HER2−/ESR1-mutated advanced/metastatic breast cancer. The company entered a license agreement with Rigel Pharmaceuticals granting exclusive global development, manufacturing, and commercialization rights. Arvinas recognized $62.5M upfront revenue from the Rigel License Agreement, $50M from an FDA approval milestone payment, and retained $112.6M from deferred Pfizer revenue recognition, for total Q2 2026 revenue of $249.7M vs. $22.4M in Q2 2025. Cash position stood at $567.9M (down from $685.4M at YE 2025, net of $114.3M operating burn YTD), sufficient to fund operations into H2 2028.

Larimar Therapeutics (market cap ~$95M) reported Q2 2026 results with $156.3M cash runway into Q3 2027. The company submitted the first module of a rolling BLA seeking accelerated approval for nomlabofusp (lead candidate for Friedreich's ataxia) in June 2026, with remaining modules expected in H2 2026. Open-label study data (43 participants dosed, 22 active, max 800 days) showed sustained skin frataxin levels comparable to asymptomatic carriers and continued clinical improvements (2.6-point mFARS benefit at 1 year vs. natural history controls). Global Phase 3 dosing targeted for Q3 2026. FDA confirmed willingness to consider frataxin as novel surrogate endpoint.

Katapult reported Q2 2026 gross originations of $75.5M (+4.7% YoY), total revenue of $74.8M (+4.0% YoY), and adjusted EBITDA of $1.2M (vs. $0.3M in Q2 2025). The company is pending an all-stock merger with Aaron's Intermediate Holdco and CCF Holdings LLC, expected to close August 2026, subject to stockholder approval. Katapult ended Q2 with $24.1M cash (including $6.0M restricted) and $74.1M revolving debt outstanding.

AdaptHealth agreed to sell its Diabetes Health business to an undisclosed buyer for $235 million in cash (23.5% of current market cap), effective immediately as discontinued operations. Simultaneously, the company slashed full-year 2026 Adjusted EBITDA guidance from $680–730 million to $490–520 million (a $190–210 million reduction, or 28–30%), citing $100M from the divestiture, $55M from West Coast capitated contract strain, $30M from manufacturer price increases, and $15M from other portfolio actions. Q2 organic revenue grew 15.9% to $740.3M, but a $144.2M goodwill impairment drove net loss of $145.3M. Free cash flow YTD turned negative at -$48.4M vs. +$73.3M prior year.

Camp4 Therapeutics completed the second closing of its private placement on August 4, 2026, raising $50.1M gross proceeds through issuance of 10.76M common shares at $1.53/share, 39,306 director/employee shares at $1.65, and 21.93M pre-funded warrants at $1.5299 each. The amendment to the original September 9, 2025 securities purchase agreement eliminates future closing tranches, making this the final closing. Investors include Coastlands Capital, Janus Henderson, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital, Trails Edge Capital Partners, and CURE SYNGAP1; net proceeds fund advancement of lead program CMP-002 for SYNGAP1-related disorder.

Theriva Biologics amended its 2020 Stock Incentive Plan on August 3, 2026, increasing the maximum shares available for grant by 2,000,000 shares, from 4,500,000 to 6,500,000 shares of common stock. The amendment is subject to stockholder approval. No specific grants, recipient names, vesting schedules, or exercise prices are disclosed in this document.

Sunoco LP reported Q2 2026 net income of $283M (vs. $86M prior year) and Adjusted EBITDA of $996M excluding transaction costs (vs. $464M), driven primarily by the Parkland Acquisition completed earlier in 2026. The company raised full-year 2026 Adjusted EBITDA guidance by $400M to $3.5–$3.7B. Distribution per unit increased 1.25% to $1.0023 per quarter ($4.0092 annualized), the seventh consecutive quarterly increase, with the distribution paid August 19, 2026 to unitholders of record August 7, 2026.

Faeth Therapeutics (formerly Sensei Biotherapeutics) completed a merger in February 2026 with concurrent $200M PIPE financing, raising cash from $21.2M (Dec 2025) to $186.4M (June 2026). The company dosed first patient in Phase 1b/2 PIK-101 breast cancer trial (April 2026) alongside ongoing Phase 2 PIK-201 endometrial cancer trial with topline data expected year-end 2026. Q2 2026 net loss was $16.0M ($2.84/share on 5.6M shares) versus $4.9M in Q2 2025; R&D expenses increased to $9.2M from $2.5M driven by PIKTOR clinical and manufacturing costs.

On August 3, 2026, Kustom Entertainment closed the sale of its Video Solutions business to Cycurion, Inc. for $1.25M cash, a $4.25M secured promissory note at 7% interest over 36 months, and $600K in Series H Preferred Stock of Cycurion yielding 12% annually. The transaction includes earn-out/clawback provisions (±$500K/year, capped $1M aggregate) based on 2026–2027 revenue targets of $5.5M and $5.8M respectively.

Steel Dynamics' board unanimously approved that Theresa E. Wagler, Executive Vice President and CFO since 2007, will become President and CEO effective January 1, 2027, replacing Mark D. Millett who founded the company over 30 years ago and will transition to Executive Chairman. Richard A. Poinsatte, currently Executive Vice President and Treasurer, will succeed Wagler as CFO. Multiple senior leadership promotions also take effect September 1, 2026, including Barry Schneider (new Chief Technology Officer role), Miguel Alvarez and James Anderson (COO expansions), and Christopher Graham (COO promotion).

SpaceX reported Q2 2026 revenues of $7.8 billion (up 92% YoY from $4.1B), with net loss of $541M (improved from $1.0B loss). The company announced a $60 billion agreement to acquire Cursor, an AI coding tool company, expected to close Q3 2026. Key developments: Starlink subscribers doubled to 12.0M; $14.1B in contracted Cloud Services Agreements signed; $6B+ in multi-year U.S. government Starshield contracts awarded; IPO raised $85.7B (June 2026); $25B bond issuance at 5.855% weighted-average rate.

Arrowhead reported Q3 FY2026 revenue of $75.3M (vs. $27.8M prior year). REDEMPLO prescriptions doubled; gained EC and Australia approvals. Plozasiran met primary endpoints in SHASTA-3/4 trials (79-81% triglyceride reduction). Company acquired FDA priority review voucher for plozasiran sNDA. Madrigal Pharmaceuticals licensed ARO-PNPLA3 with $25M upfront, up to $975M milestones, and royalties. Net loss widened to $194.3M from $175.2M YoY due to R&D spend of $198.2M. Cash resources total $1.57B.

Seres Therapeutics terminated its lease at 200 Sidney Street, Cambridge, MA (executed July 31, 2026, effective December 31, 2026). Payment to landlord BMR-Sidney Research Campus LLC comprises: (1) $2.24M letter-of-credit increase (total $3.64M, applied to rent through lease end); (2) $3.85M termination fee (due January 4, 2027); (3) 103,520 shares of common stock valued at $500K (share count calculated as $500K ÷ closing price on Nasdaq July 31, 2026, issued within 5 business days). Company retains 47,341 sq ft on three floors through December 31, 2026; AbbVie's 21,295 sq ft subleased space (floors 1 & 4) surrendered immediately. Total lease obligation reduction from ~68,636 sq ft to 47,341 sq ft.

Lattice Semiconductor completed its $1.65 billion acquisition of AMI on July 27, 2026, comprised of ~$1 billion cash and $650 million in stock (~5.2M shares issued). Q2 2026 revenue reached record $201.1M (62% YoY growth); non-GAAP EPS of $0.53 (up 120% YoY). AMI expected to contribute >$200M revenue in 2026 with 75%+ gross margins and 40% EBITDA margins; deal expected accretive to gross margin, EBITDA, FCF, and EPS on non-GAAP basis.

Q2 2026: Total revenue $22.4M (+30% YoY); clinical revenue $2.6M (+442% YoY) on 10,384 tests (+199% YoY); pharma testing $16.8M (+51% YoY); cash position $212.7M. Medicare approvals secured for NeXT Personal in IO monitoring and neoadjuvant breast cancer. On July 20, 2026, Personalis announced agreement to be acquired by Tempus AI, Inc.; company will cease quarterly guidance and earnings calls.

Zeta Global reported Q2 2026 revenue of $443M (44% YoY growth), exceeding guidance midpoint by $23M (5%). The company achieved positive GAAP net income of $8M ($0.03 EPS) and $92M adjusted EBITDA (20.7% margin). Guidance raised: FY2026 revenue now $1,818M midpoint (up $33M), adjusted EBITDA $405.2M midpoint (up $7.9M), free cash flow $255.3M (up $20.3M), and GAAP EPS $0.10 (up $0.07 from prior $0.02–$0.04 range). Super-Scaled Customers grew 17% YoY to 197; ARPU increased 17% to $1.8M.

Precigen achieved Q2 2026 net income of $20.1M ($0.06/share basic) on PAPZIMEOS product revenues of $53.1M, more than double Q1 2026. The company reached cash flow profitability milestone with 500+ patients enrolled in patient hub, 7-year FDA market exclusivity, permanent J-code (J3404), and payer coverage across ~315M US lives (~100% insured). Cash position of $38.7M (cash, equivalents, investments) is expected to support cash flow break-even by end of 2026.

Jeffrey W. Kip (CEO) received amended PSU award of 280,000 shares (dated August 3, 2026) with tranched vesting over 3–4 years tied to service conditions or stock price targets ($45–$60). Simultaneously, Angi recorded $235.2M non-cash goodwill impairment and $9.6M intangible asset impairment in Q2 2026, driving operating loss of $(233.7)M. Revenue fell 11% YoY to $248.0M; Adjusted EBITDA declined 14% to $28.2M. Company repurchased $100M debt principal for $91.9M since March 2026.

MasterBrand completed an all-stock merger with American Woodmark on May 28, 2026, creating a combined entity with $4.1B trailing-twelve-month revenue. The company raised its annual run-rate cost synergy target to over $100M by end of year three post-close (from an original target), with $30M of synergies already executed by July 31, 2026 and $15M expected in H2 2026. However, Q2 2026 showed legacy MasterBrand net loss of $28.7M (vs. $37.3M income in Q2 2025) and adjusted EBITDA margin compression of 600 basis points to 8.4%, driven by mid-to-high-single-digit market decline, unfavorable product mix, and inflation, only partially offset by tariff mitigation and cost actions. Net debt increased to $1,148.7M (3.9x leverage on combined adjusted EBITDA of $294.5M TTM), and free cash flow turned negative at $(17.6)M YTD.

Bed Bath & Beyond reported Q2 2026 net revenue of $361M (+28% YoY), marking its second consecutive quarter of revenue growth after 19 consecutive quarters of decline. Active customers grew 47% YoY to 6.4M; orders delivered rose 117% YoY to 2.8M. The parent company will rebrand to Neighborhood Intelligence, trade on Nasdaq under ticker NXH (starting August 17, 2026), and relocate headquarters to Nashville, Tennessee. Company plans to eliminate $50M+ in annualized costs within 12 months by consolidating recently acquired businesses (The Brand House Collective/Kirkland's brands, The Container Store, Elfa, Closet Works; pending: Fathom Holdings, F9 Brands, Lumber Liquidators, Cabinets To Go) onto a unified platform.

Arvinas and Pfizer (joint licensors) granted exclusive worldwide license of Vepdegestrant to Rigel Pharmaceuticals effective May 11, 2026. Rigel pays $70M upfront fee plus up to $85M in milestone payments and royalties on net sales. Deal transfers regulatory materials (Approved NDA 219835), manufacturing responsibility, and commercialization to Rigel while Pfizer completes ongoing clinical studies. Arvinas' CMO Noah Berkowitz separated July 3, 2026 with 9-month salary continuation.

Astera Labs reported Q2 2026 GAAP revenue of $392.4M (up 27% QoQ, 104% YoY) with 73.3% gross margin and $153.1M net income ($0.83 diluted EPS). The company guided Q3 2026 revenue to $540–560M with Scorpio X-Series 320-lane fabric switch production ramping one quarter ahead of prior expectations, marking the company's evolution into a complete AI fabric infrastructure provider. No material M&A, financing, or operational disruptions disclosed.

Flotek reported Q2 2026 revenue of $99.4M (+70% YoY) with net income of $10.0M (+463% YoY) and Adjusted EBITDA of $16.8M (+109% YoY). The company raised full-year 2026 guidance: total revenue from $270–$290M to $340–$350M (+26% midpoint), and Adjusted EBITDA from $36–$41M to $47–$51M (+27% midpoint). On August 3, 2026, Flotek announced a 10-year contract with Puerto Rico Electric Power Authority (PREPA) worth ~$400M backlog (~$40M annually) to support a 400 MW gas power project via its PWRtek platform; guidance excludes this contract's impact. Data Analytics segment achieved record quarterly revenue of $19.2M (+223% YoY), with external customers representing 63% of segment revenue.

Devon Energy closed its merger with Coterra Energy on May 7, 2026 (94 days post-announcement), creating a combined company. Q2 2026 results exceeded guidance: oil production averaged 503,000 bbl/d (top-end), total production 1,359,000 Boe/d, capital expenditures $1,269M (2% below midpoint), adjusted free cash flow $1.7B. The company acquired 16,300 net acres in Delaware Basin for $2.6B at the New Mexico federal lease sale. Devon targets at least $1.0B in annual pre-tax synergies by end-2027, with ~$600M expected in 2027. Returned $1,063M to shareholders via 33% dividend increase ($0.32/share), $197M in share repurchases (4.3M shares), and $500M debt repayment. Net debt stands at $10.4B; net debt-to-EBITDAX at 1.2x.

Bruce Bernstein, beneficial owner of 339,882 XWELL common shares (~9.4% of company based on public float), entered a Support Agreement dated July 6, 2026 with Express Wellness Group, LLC (Buyer). Bernstein agrees to vote all his shares in favor of a Securities Purchase Agreement and the sale transaction, and grants Buyer a proxy if he fails to comply. He cannot transfer shares (except to affiliates or family), solicit alternative transactions, or form competing groups. The agreement terminates upon deal closing, valid termination of the purchase agreement, or an adverse board recommendation change.

Corebridge Financial reported Q2 2026 results with shareholder approval of its merger with Equitable Holdings on July 30, 2026. The company posted a net loss of $16 million ($0.04 per share) on a GAAP basis but adjusted after-tax operating income of $512 million ($1.12 per share). Premiums and deposits declined 13% to $9.1 billion year-over-year; the company returned $412 million to shareholders via $300 million in repurchases and $112 million in dividends, and declared a $0.25 dividend per share.

IFF announced a definitive agreement to sell its Food Ingredients disposal group to CVC Capital Partners for approximately $3.8 billion net proceeds (with 10% minority retained), expected to close by end of Q2 2027. IFF will reduce debt by >$1B and execute a $2.5B share repurchase program ($500M accelerated in H2 2026, remaining $2B post-close by end of 2027). The company expects to eliminate ~$100M in stranded costs within two years. Q2 2026 continuing operations showed sales of $1.95B (+2% reported, +6% currency-neutral), adjusted EBITDA of $408M, and EPS ex-amortization of $0.82.

Zimmer, Inc. agreed to acquire all shares of Pacira CryoTech, Inc. (a handheld cryoanalgesia device company) from Pacira BioSciences, Inc. for $70M base consideration (dated June 28, 2026). Additional contingent payments: up to $70M in milestone payments tied to Net Revenue thresholds ($50M–$70M) over 2027–2031, plus $1M Spasticity Collaborative Adjustment. Asset Purchase Price is $34.85M; Share Purchase Price is the remainder. Significant representations cover FDA/regulatory compliance, IP ownership, no material litigation, and employee matters. Seller subject to 5-year non-compete and 10-year confidentiality covenants.

Travere Therapeutics entered into an exclusive license and collaboration agreement with Everest Medicines (Singapore) dated June 1, 2026, to develop and commercialize EVER001 (a reversible BTK inhibitor) worldwide except for retained Asian territories. Travere paid $112.5M upfront, will pay development/regulatory/commercial milestone payments, and tiered royalties on net sales. Everest retains rights in Asia (Mainland China, Hong Kong, Taiwan, Korea, Southeast Asia). The parties will share development costs for global trials; Travere leads Territory development and commercialization; Everest continues ongoing Phase 1b/2a trial and retained territory rights.